Study Details

Back to Search Results

A Study to Evaluate ASP8232 in Reducing Central Retinal Thickness in Subjects with Diabetic Macular Edema (DME)

This trial is complete
The study has ended normally, and participants are no longer being examined or treated (that is, the last participant's last visit has occurred).

Clinicaltrials.gov ID

The unique identification code given to each clinical study upon registration at ClinicalTrials.gov.
NCT02302079

Astellas Study ID

The unique identification code given by the study sponsor.

8232-CL-3001

EudraCT ID

The unique identification code given to each clinical study upon registration at EudraCT (European Union Drug Regulating Authorities Clinical Trials Database).

N/A

Follow Trial

Condition

Diabetes, Eye Disorders

Phase

These clinical trials are done to learn if an experimental treatment helps participants who have a specific condition or disease. Phase 2 trials usually include a larger group of participants than Phase 1 trials.

Phase 2

Age

18 years - 85 years

Sex

Female & Male

Product

N/A

Type

A type of clinical study in which participants are assigned to groups that receive one or more intervention/treatment (or no intervention) so that researchers can evaluate the effects of the interventions on biomedical or health-related outcomes.

Interventional

Trial Dates

Jan 2015 - Aug 2016

Masking

Triple (Participant, Investigator, Outcomes Assessor)

Enrollment number

96

A Phase 2, Double-Masked, Randomized, Active Controlled Study to Evaluate the Efficacy and Safety of ASP8232 in Reducing Central Retinal Thickness in Subjects with Diabetic Macular Edema

Study summary

Study documents

Study Documents, including study results, are available after a study is completed or terminated, according to Astellas Transparency policy.

Get More Information

Would you like more information about clinical trial sites that are recruiting participants for A Study to Evaluate ASP8232 in Reducing Central Retinal Thickness in Subjects with Diabetic Macular Edema (DME)? Contact us by filling our your information to the right and we’ll respond to you.

By clicking ["Continue/Submit"], you agree that Astellas may contact you by email with information to help you connect with clinical trial sites. While we can connect you to clinical trial sites, we cannot answer questions about any investigational therapy through email. Your consent to receiving emails is not a requirement to participate in a clinical trial or study. For more information, including how to unsubscribe at any time, see our Privacy Notice & Cookies Policy.

Locations

Site US10021

Phoenix, United States, 85104

Site US10012

Nashville, United States, 37203

Site US10013

Houston, United States, 77030

Site US10031

Santa Ana, United States, 92705

Site US10036

Augusta, United States, 30909

Site US10009

San Antonio, United States, 78240-1502

Site US10022

Lynbrook, United States, 11563

Site US10007

Palm Desert, United States, 92260

Site US10032

Fort Worth, United States, 76102

Site US10027

Reno, United States, 89511

Site US10005

Winter Haven, United States, 33880

Site US10017

Charlottesville, United States, 22903

Site US10004

Beverly Hills, United States, 90211

Site US10025

Tucson, United States, 85704

Site US10030

McAllen, United States, 78503

Site US10011

Sacramento, United States, 95819

Site US10006

Arcadia, United States, 91007

Site US10010

Abilene, United States, 79606

Site US10002

Boston, United States, 02114

Site US10029

Golden, United States, 80401

Site US10016

Miami, United States, 33126

Site US10001

Omaha, United States, 985540

Site US10015

Austin, United States, 78705

The purpose of this website is to offer education and information to patients and their families and friends, the public, and healthcare professionals about the clinical trial process. In addition, the website will provide specific information about Astellas clinical trials. Please read the complete Astellas Transparency Policy to learn about the clinical trial information available on this website

© ASTELLAS PHARMA GLOBAL DEVELOPMENT, INC.

POWERED BY:

Pharma Intelligence logo